Use of Injectable CAB/RPV LA as Replacement ART in Virally Suppressed Adults

April 2022

Table 3: Optional Lead-in, Initiation, and Maintenance for BIMONTHLY CAB/RPV LA Dosing [a,b]

Timing	Dosing and Administration	Comments
Optional oral lead-in: Month 0	CAB 30 mg/RPV 25 mg once daily by mouth with a meal x 4 weeks	Oral medication lead-in
Month 1	CAB 600 mg (3 mL)/RPV 900 mg (3 mL) IM injection	**Initiation dose:** Administer on last day of oral lead-in or prior suppressive ART regimen
Month 2	CAB 600 mg (3 mL)/RPV 900 mg (3 mL) IM	**Maintenance dose:** Administer within 7 days before or after scheduled date (see *Managing Missed or Delayed Injections*)
Month 4 and every 2 months thereafter	CAB 600 mg (3 mL)/RPV 900 mg (3 mL) IM	**Maintenance dose:** Administer within 7 days before or after scheduled date (see *Managing Missed or Delayed Injections*)

Abbreviations: ART, antiretroviral therapy; CAB, cabotegravir (brand name Vocabria); CAB/RPV LA, injectable long-acting cabotegravir/rilpivirine (brand name Cabenuva); IM, intramuscular; RPV, rilpivirine (brand name Edurant).

Notes:

a. [ViiV Healthcare 2022]
b. [FDA 2021]

References

FDA. Cabenuva (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use. 2021 Jan. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212888s000lbl.pdf [accessed 2021 Mar 08]

ViiV Healthcare. ViiV Healthcare announces US FDA approval of cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment. 2022 https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2022/january/viiv-healthcare-announces-fda-approval-of-cabenuva-for-use-every-two-months/ [accessed 2022 Feb 9]